Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lusvertikimab - OSE Immunotherapeutics/Servier

Drug Profile

Lusvertikimab - OSE Immunotherapeutics/Servier

Alternative Names: Anti CD127 monoclonal antibody - OSE Immunotherapeutics; Anti IL7R - Servier; Anti interleukin-7 receptor-α monoclonal antibody - OSE Immunotherapeutics; Effi-7; IL-7 receptor antagonist - OSE Immunotherapeutics; Interleukin-7 receptor antagonist - OSE Immunotherapeutics; OSE-127; OSE-217; S-95011

Latest Information Update: 01 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Effimune
  • Developer OSE Immunotherapeutics; Servier; University Hospital Schleswig-Holstein
  • Class Anti-inflammatories; Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Interleukin 7 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Ulcerative colitis
  • Phase II Sjogren's syndrome
  • Preclinical Precursor B-cell lymphoblastic leukaemia-lymphoma
  • Discontinued Crohn's disease; Transplant rejection

Most Recent Events

  • 01 Dec 2023 Phase-III clinical trials in Ulcerative colitis (Parenteral) before December 2023 (OSE Immunotherapeutics pipeline, December 2023)
  • 06 Jul 2023 EMA’s Committee for Orphan Medicinal Products (COMP) grants a positive opinion for the designation of orphan medicine to Lusvertikimab for the treatment of Acute Lymphoblastic Leukemia (ALL)
  • 06 Jul 2023 OSE Immunotherapeutics received a positive review from the Drug Safety Monitoring Board (DSMB) for a phase II trial of Lusvertikimab (OSE127) in Ulcerative colitis
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top